Media Summary: This presentation discussed the ANDA landscape for topical products applied to the skin and identified challenges associated ... This presentation explained factors that could impact first-cycle bioequivalence (BE) adequacy based on observed BE ... The second of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference.
Agdd 2024 D2s10 2 Analysis - Detailed Analysis & Overview
This presentation discussed the ANDA landscape for topical products applied to the skin and identified challenges associated ... This presentation explained factors that could impact first-cycle bioequivalence (BE) adequacy based on observed BE ... The second of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference. This presentation provided an overview of the current use of Comparative Use Human Factors (CUHF) studies to support various ... The second of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. This presentation addressed safety concern thresholds for extractables and leachables in ANDA submissions and covered ...
Closing remarks from day two of the Advancing Generic Drug Development Conference delivered by Dr. Robert Lionberger. This presentation provided key principles for comparative The final Q&A discussion panel from day one of the Advancing Generic Drug Development Conference. ***No Timestamps*** ... This presentation discussed in silico methodologies for topical products applied to the skin, with particular focus on dermal ... The first of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference. The final Q&A discussion panel from day two of the Advancing Generic Drug Development Conference. ***No Timestamps*** ...
This presentation described how ongoing research contributes to the evolution of Product-Specific Guidances (PSGs) for topical ...
